Charles River Laboratories | CRL - Gross Profit On Sales

Stock Price
189.24
Daily Change
5.54 3.02%
Monthly
-12.70%
Yearly
15.54%
Q1 Forecast
204.00

Charles River Laboratories reported $311.39M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Agilent USD 990M 102M Sep/2025
Align Technology USD 683.59M 44.39M Dec/2025
Bio-Rad Laboratories USD 345.3M 34.7M Jun/2025
Bruker USD 379.4M 21.5M Sep/2025
Cardinal Health USD 2.4B 78M Dec/2025
Charles River Laboratories USD 311.39M 6.77M Sep/2025
Cigna USD 56.45B 50.29B Sep/2025
CVS Health USD 13.81B 213M Sep/2025
Danaher USD 3.97B 443M Dec/2025
Dentsply International USD 441M 49M Sep/2025
Elevance Health USD 11.68B 889M Dec/2025
Galapagos EUR -13.57M 74.82M Sep/2025
Hologic USD 586.4M 2.9M Dec/2025
Humana USD 4.82B 754M Jun/2025
Illumina USD 759M 26M Dec/2025
Incyte USD 1.27B 130.22M Sep/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
Laboratory Of America USD 1.03B 21.1M Sep/2025
Lonza CHF 1.29B 248M Jun/2025
McKesson USD 3.68B 143M Dec/2025
Merck EUR 3.21B 186M Sep/2025
Mettler Toledo International USD 675.44M 65.98M Dec/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Quest Diagnostics USD 910M 6M Sep/2025
Revvity USD 374.6M 17.95M Sep/2025
Thermo Fisher Scientific USD 4.64B 419M Dec/2025
United Therapeutics USD 602.1M 108.9M Sep/2025
UnitedHealth USD 20.64B 77.96B Sep/2025
Waters USD 459.99M 21.97M Sep/2025
West Pharmaceutical Services USD 294.3M 20.4M Sep/2025